Publicaciones en colaboración con investigadoras/es de Hospital Universitario 12 de Octubre (28)

2022

  1. Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer’s Disease Patients

    Frontiers in Immunology, Vol. 13

  2. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  2. Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1

2020

  1. Decreased salivary lactoferrin levels are specific to Alzheimer's disease

    EBioMedicine, Vol. 57, pp. 102834

  2. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  3. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

2018

  1. Consensus document on exclusion diets in irritable bowel syndrome (IBS)

    Nutricion Hospitalaria, Vol. 35, Núm. 6, pp. 1450-1466

  2. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

2017

  1. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 8, pp. 131-138

2015

  1. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration

    Colloids and Surfaces B: Biointerfaces, Vol. 134, pp. 304-313

  2. Enhanced hippocampal neurogenesis in APP/Ps1 mouse model of alzheimer’s disease after implantation of VEGF-loaded PLGA nanospheres

    Current Alzheimer Research, Vol. 12, Núm. 10, pp. 932-940

  3. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease

    Journal of Controlled Release, Vol. 203, pp. 170-180

  4. Optimizing the dosing regimen of linezolid in critically ill septic patients undergoing continuous hemodiafiltration using a pharmacokinetic/pharmacodynamic analysis and Monte Carlo simulation

    Intensive Care Medicine Experimental

  5. Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy

    Intensive Care Medicine Experimental

2014

  1. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model

    Neurobiology of Aging, Vol. 35, Núm. 7, pp. 1582-1595

  2. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 1, pp. 180-189

2013

  1. Intranasal Delivery of Plasma and Platelet Growth Factors Using PRGF-Endoret System Enhances Neurogenesis in a Mouse Model of Alzheimer's Disease

    PLoS ONE, Vol. 8, Núm. 9

  2. VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease

    Journal of Controlled Release, Vol. 170, Núm. 1, pp. 111-119